InsiderLens
All transactionsBrowse millions of insider transactions
Top buysLargest insider purchases
Top sellsLargest insider sales
Cluster activityMultiple insiders trading together
All companiesBrowse all 22,000+ companies
ScreenerFilter by sector, country, activity
By countryBrowse by market
All InsidersBrowse all 240,000+ Insiders
Most activeInsiders with the most trades
Best performersHighest returns on insider buys
Alerts

Global search

Find a company or insider, or run a shortcut.

InsiderLens

Track insider trading activity, analyze financial data, and monitor insider transactions across global markets.

Transactions

  • Top buys
  • Top sells
  • Companies
  • Insiders
  • Screener

Resources

  • API
  • Blog
  • Help center
  • Methodology

Company

  • About
  • Contact
  • Privacy policy
  • Terms of service
  • Cookie policy

Data sources: SEC EDGAR (US) · AMF / BDIF (FR) · BaFin (DE) · FCA (GB) · FSMA (BE) · AFM (NL) · CNMV (ES) · SIX (CH) · FI (SE) · Oslo Børs (NO) · Nasdaq Nordic & Baltic · and 20+ other European regulators.

The information provided on InsiderLens is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Insider transaction data is sourced from public regulatory filings. Past insider transactions do not guarantee future performance. Always consult a qualified financial advisor before making investment decisions.

© 2026 InsiderLens

  1. Home
  2. /
  3. Insiders
  4. /
  5. Bisker-Leib Vered

Bisker-Leib Vered

BalancedHigh Signal
C-SuiteCOMPEX TECHNOLOGIES INC·BoardAdvaxis, Inc.·BoardAyala Pharmaceuticals, Inc.·C-SuiteCENTURY PROPERTIES GROWTH FUND XXIICIK 0001814093
20 transactions·4 companies·Last Feb 8, 2024
$00 buys
$00 sells
50%/50%3.1M shares held ≈ $18.7M
C SUITECEOSENIOR EXECUTIVEatCOMPEX TECHNOLOGIES INCCMPX

Last filing: Apr 2026

BOARD MEMBERatAdvaxis, Inc.ADXS

Last filing: Apr 2026

BOARD MEMBERatAyala Pharmaceuticals, Inc.AYLA

Last filing: Apr 2026

+ 1 more company

Also at COMPEX TECHNOLOGIES INC

SJ
Schuetz Thomas J.
CEO69 tx
GW
GLADNEY DAN W
CEO10 tx
SB
Shin Barry
CFO33 tx
YP
YOUNGSTROM SCOTT P
CFO10 tx
LN
Lerner Neil
C SUITE40 tx

Insider transactions by Bisker-Leib Vered

20 transactions — - in purchases, - in sales

DateViaCompanyTypeSharesValue
Feb 8, 24DirectCMPXCOMPEX TECHNOLOGIES INCOther49 198$71 337
Jan 9, 24DirectCMPXCOMPEX TECHNOLOGIES INCGrant1 753 125-
Jan 9, 24DirectCMPXCOMPEX TECHNOLOGIES INCGrant1 753 125$3 383 531
Nov 17, 23DirectCMPXCOMPEX TECHNOLOGIES INCOther64 415$96 623
Feb 8, 23DirectCMPXCOMPEX TECHNOLOGIES INCGrant600 000-
Feb 8, 23DirectCMPXCOMPEX TECHNOLOGIES INCGrant400 000-
Jan 19, 23DirectADXSAdvaxis, Inc.Grant1 171-
Jan 19, 23DirectADXSAdvaxis, Inc.Grant1 171-
Jan 19, 23DirectADXSAdvaxis, Inc.Grant1 639-
Jan 19, 23DirectAYLAAyala Pharmaceuticals, Inc.Disposition8 750-
Jan 19, 23DirectAYLAAyala Pharmaceuticals, Inc.Disposition6 250-
Jan 19, 23DirectAYLAAyala Pharmaceuticals, Inc.Disposition6 250-
Jun 13, 22DirectAYLAAyala Pharmaceuticals, Inc.Grant6 250-
Feb 18, 22DirectCMPXCOMPEX TECHNOLOGIES INCGrant500 000-
Feb 17, 22DirectCMPXCOMPEX TECHNOLOGIES INCGrant500 000-
Nov 16, 21DirectNONECENTURY PROPERTIES GROWTH FUND XXIIGrant600 000-
Jun 10, 21DirectAYLAAyala Pharmaceuticals, Inc.Grant6 250-
Feb 9, 21DirectCMPXCOMPEX TECHNOLOGIES INCGrant400 000-
Aug 18, 20DirectAYLAAyala Pharmaceuticals, Inc.Grant8 750-
Aug 6, 20DirectNONECENTURY PROPERTIES GROWTH FUND XXIIGrant600 000-
Direct = personal transaction
Via entity / trust / associate

Frequently asked questions about Bisker-Leib Vered

What are Bisker-Leib Vered's recent insider transactions?

Bisker-Leib Vered has filed 20 insider transactions across 4 companies, totaling $0 in purchases and $0 in sales. The most recent filing was on February 8, 2024.

Is Bisker-Leib Vered a net buyer or seller of shares?

Based on regulatory disclosures, Bisker-Leib Vered is a net seller with 0 purchases and 0 sales on record.

Data sourced from public regulatory filings (SEC EDGAR, AMF, BaFin). This information is provided for educational purposes and does not constitute investment advice, a recommendation, or a solicitation to buy or sell securities.

Updated February 8, 2024·Full disclaimer